De Pradip, Carlson Jennifer, Leyland-Jones Brian, Dey Nandini
Department of Molecular and Experimental Medicine, Avera Research Institute, Sioux Falls, SD; Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD.
Oncotarget. 2014 Jul 15;5(13):4581-602. doi: 10.18632/oncotarget.2127.
Oncoprotein CIP2A a Cancerous Inhibitor of PP2A forms an "oncogenic nexus" by virtue of its control on PP2A and MYC stabilization in cancer cells. The expression and prognostic function of CIP2A in different solid tumors including colorectal carcinoma, head and neck cancers, gastric cancers, lung carcinoma, cholangiocarcinoma, esophageal cancers, pancreatic carcinoma, brain cancers, breast carcinoma, bladder cancers, ovarian carcinoma, renal cell carcinomas, tongue cancers, cervical carcinoma, prostate cancers, and oral carcinoma as well as a number of hematological malignancies are just beginning to emerge. Herein, we reviewed the recent progress in our understanding of (1) how an "oncogenic nexus" of CIP2A participates in the tumorigenic transformation of cells and (2) how we can prospect/view the clinical relevance of CIP2A in the context of cancer therapy. The review will try to understand the role of CIP2A (a) as a biomarker in cancers and evaluate the prognostic value of CIP2A in different cancers (b) as a therapeutic target in cancers and (c) in drug response and developing chemo-resistance in cancers.
癌蛋白CIP2A是一种PP2A的癌性抑制剂，通过控制癌细胞中的PP2A和MYC稳定性形成“致癌关联”。CIP2A在包括结直肠癌、头颈癌、胃癌、肺癌、胆管癌、食管癌、胰腺癌、脑癌、乳腺癌、膀胱癌、卵巢癌、肾细胞癌、舌癌、宫颈癌、前列腺癌和口腔癌在内的不同实体瘤以及一些血液系统恶性肿瘤中的表达和预后功能才刚刚开始显现。在此，我们综述了近期在理解以下两方面的进展：（1）CIP2A的“致癌关联”如何参与细胞的致瘤转化；（2）在癌症治疗背景下，我们如何展望/看待CIP2A的临床相关性。该综述将试图了解CIP2A作为（a）癌症生物标志物的作用，并评估CIP2A在不同癌症中的预后价值；（b）癌症治疗靶点的作用；以及（c）在癌症药物反应和化疗耐药性发展中的作用。
